Tumor necrosis factor receptor superfamily member 17 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Tumor necrosis factor receptor superfamily member 17 shows approved-linked disease relevance led by multiple myeloma. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q02223. Start with multiple myeloma, then reuse UniProt Q02223 as the stable protein anchor across project notes and exports.
Start with multiple myeloma, then reuse UniProt Q02223 as the stable protein anchor across project notes and exports.
Tumor necrosis factor receptor superfamily member 17 shows approved-linked disease relevance led by multiple myeloma. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with multiple myeloma because it currently carries approved-linked support. Linked drugs include BELANTAMAB MAFODOTIN, CILTACABTAGENE AUTOLEUCEL, ELRANATAMAB, IDECABTAGENE VICLEUCEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTumor necrosis factor receptor superfamily member 17
Review this target as Tumor necrosis factor receptor superfamily member 17, mapped to UniProt Q02223. Sequence length is 184 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tumor necrosis factor receptor superfamily member 17 as ChEMBL target CHEMBL4523587, mapped to UniProt Q02223. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tumor necrosis factor receptor superfamily member 17 is the right protein anchor across sources, using UniProt Q02223 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why multiple myeloma is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tumor necrosis factor receptor superfamily member 17 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q02223 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tumor necrosis factor receptor superfamily member 17 |
| UniProt Accession | Q02223 |
| Component Type | Protein |
| Sequence Length | 184 aa |
Tumor necrosis factor receptor superfamily member 17
Review this target as Tumor necrosis factor receptor superfamily member 17, mapped to UniProt Q02223. Sequence length is 184 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Tumor necrosis factor receptor superfamily member 17 shows approved-linked disease relevance led by multiple myeloma. 5 more disease programs remain visible in the same review block.
Start review with multiple myeloma because it currently carries approved-linked support. Linked drugs include BELANTAMAB MAFODOTIN, CILTACABTAGENE AUTOLEUCEL, ELRANATAMAB, IDECABTAGENE VICLEUCEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.